Pfizer Inc announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of people with relapsed or refractory multiple myeloma (RRMM). Elranatamab is a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb).
- Read more about Pfizer's Elranatamab Granted FDA Breakthrough Therapy Designation
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/pfizer-elranatamab-granted-fda-breakthrough-therapy-designation
No comments:
Post a Comment